Medical Tidbits, Surgeons with Jewish Hospital/University of Louisville/University of Louisville Physicians Perform First Islet Cell Auto-transplantation Procedures in Kentucky


LOUISVILLE, Ky.–(EON: Enhanced Online News)–People with a debilitating and painful disease have a new treatment option available to them thanks to the collaborative efforts of Jewish Hospital, the University of Louisville and the University of Louisville Physicians.  read more

Former Executive at Novartis Joins Myriad’s International Leadership Team

“Our international business represents a significant long-term growth opportunity for Myriad and the European region is our biggest near-term opportunity,” said King. “We are delighted to welcome Jan Schlüchter as our new chief commercial officer. His experience in leading and transforming healthcare businesses will help us accelerate growth internationally.”

Myriad Genetics GmbH is the Zurich-based international subsidiary of Myriad Genetics, Inc. and oversees the international operations outside the United States. As the CCO, Dr. Schlüchter will lead country operations in Europe to drive new growth opportunities, offering superior molecular diagnostic solutions for patients, physicians and payors. He will focus on commercializing the Company’s portfolio of hereditary cancer tests, companion diagnostics and high-value test kits.

U.S. FDA Approves JUVEDERM® ULTRA XC for Use in Lips/ First and Only Filler Approved for Lip Augmentation that Lasts Up to One Year

DUBLIN, Oct. 1, 2015 /PRNewswire/ — Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVEDERM® ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM® ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation. read more

Sarepta Therapeutics Announces Additional Long-Term Efficacy and Safety Data from Pivotal Phase IIb Program of Eteplirsen for Treatment of Duchenne Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 1, 2015– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced additional clinical efficacy and safety data from the Company’s Phase IIb program of eteplirsen in patients with Duchenne muscular dystrophy (DMD). The data demonstrated that eteplirsen provided a statistically significant advantage of 151 meters in the ability of study participants to walk at three years, compared with external controls. Further, the fourth biopsy data confirmed the mechanism of action of eteplirsen, demonstrating exon skipping in all patients and dystrophin production in nearly all patients. Safety data remained consistent with prior results. read more

Exactech Announces Successful First Surgeries with New Revision Knee System

GAINESVILLE, Fla.–(EON: Enhanced Online News)–Exactech, Inc. (Nasdaq: EXAC), a worldwide developer and producer of bone and joint restoration products, announced today the successful first surgeries performed with its new revision knee system. Designed to provide a reproducible surgical technique for treating complex revision total knee replacement patients, the system includes a comprehensive implant offering and ergonomically designed instrumentation. Pilot launch is scheduled through the remainder of the year with full market availability in the United States in 2016. read more

ORBERA™ Intragastric Balloon Recognized by the American Society for Gastrointestinal Endoscopy as Meeting ASGE Criteria for the Treatment of Obesity

AUSTIN, Texas–(EON: Enhanced Online News)–Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, is proud to announce the ORBERA™ Intragastric Balloon has met the American Society for Gastrointestinal Endoscopy’s (ASGE) Preservation and Incorporation of Valuable Endoscopic Innovations (PIVI) threshold standards for the treatment of obesity. read more

RecoSMA® – A New Hope for Liver Cirrhosis Patients

Liver Regeneration Evidence Revealed in Scientific Study

Liver cirrhosis is a disease caused by long-term damage through infection, obesity and alcohol abuse amongst other reasons. It is now the fifth biggest killer in the UK[1]. The only option for end-stage cirrhosis is liver transplantation. Globally more than a million people die yearly from liver disease[2] some waiting for a suitable donor organ. read more




Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.